Garonit Pharmaceutical, Inc. plans to build a 200,000-square-foot pharmaceutical manufacturing facility in New Windsor, Orange County. The $46.1 million investment will make the facility the largest producer of chlorhexidine gluconate globally, an antiseptic widely used for surgical disinfection and infection prevention in hospitals.
The State of New York is providing $3.8 million in support for the project. This includes up to $3.5 million from the Excelsior Jobs Program and a $300,000 grant from the Mid-Hudson Regional Economic Development Council.
According to Governor Kathy Hochul, “New York is leading the way in reshoring pharmaceutical manufacturing, strengthening supply chains and creating high-quality jobs — and Garonit Pharmaceutical’s decision to invest in Orange County is proof of that progress,” Governor Hochul said. “This world-class facility will produce essential antiseptic products used in surgical and hospital settings around the globe, further positioning our state as a leader in the life sciences sector. With this investment, we are not only creating good-paying jobs but also reaffirming that New York is where innovation and opportunity meet.”
Empire State Development President, CEO, and Commissioner Hope Knight commented on the announcement: “Garonit Pharmaceutical’s expansion into New York reflects the confidence that global companies have in our state’s workforce, infrastructure, and innovation ecosystem. The Mid-Hudson region’s strategic location, robust infrastructure, and proximity to world-class transportation networks make it an ideal location for advanced manufacturing operations. This project will generate long-term economic benefits and position the region for continued growth in the pharmaceutical sector.”
The new facility is expected to create 100 skilled jobs locally while increasing production capacity for critical antiseptic products needed by hospitals worldwide.
